Evidence map›Paper›PMID 39921609›Full record

ArticleJournal of medical virology2025

Adenovirus-Specific T Cells in Adults Are Frequent, Cross-Reactive to Common Childhood Adenovirus Infections and Boosted by Adenovirus-Vectored Vaccines.

Rookmini Mukhopadhyay, Arnold W Lambisia, Jennifer P Hoang, Benjamin J Ravenhill, Charles N Agoti, Benjamin A Krishna, Charlotte J Houldcroft

Abstract read
In one paragraph

Article in Journal of medical virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. The immunogenicity and safety of adenoviral-based vaccines.Current opinion in allergy and clinical immunology · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rookmini MukhopadhyayDepartment of Genetics, University of Cambridge, Cambridge, UK.
Arnold W LambisiaKenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya.
Jennifer P HoangDepartment of Genetics, University of Cambridge, Cambridge, UK.
Benjamin J RavenhillCambridge Institute for Medical Research, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
Charles N AgotiKenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya.
Benjamin A KrishnaDepartment of Medicine, University of Cambridge, Cambridge, UK.
Charlotte J HouldcroftDepartment of Genetics, University of Cambridge, Cambridge, UK.ORCID 0000-0002-1833-5285

Funding

This study was supported by Cambridge-Africa ALBORADA (CNA and CJH), Royal Society (CJH [RGS\R2\222009]), and Wellcome Trust (225023/Z/22/Z).Wellcome TrustWellcome Trust 225023/Z/22/Z
6 · The paper itself

Abstract

Human adenoviruses (HAdVs) cause diverse disease presentations as pathogens and are also used as viral vectors for vaccines and gene therapy products. Pre-existing adaptive immune responses to HAdV are known to influence symptom severity, viral clearance and the success of viral vectored products. Of note, approximately 50% of the UK's adult population has received at least one dose of a chimpanzee adenovirus vectored SARS-CoV-2 vaccine (ChAdOx1) since January 2021. We used FluoroSpot analysis to quantify the interferon-gamma (IFNγ) and interleukin-2 (IL2) responses of healthy blood donors to HAdV species A, B, C, D and F and chimpanzee adenovirus Y25, related to HAdV species E. We find that cellular immune responses to multiple species of human adenovirus are ubiquitous among healthy adult blood donors and that stimulating PBMC with whole hexon peptide libraries induces a significantly greater IFNγ and IL2 response than using selected peptide pools alone. We then compared the cellular immune responses of ChAdOx1 recipients and control donors using PBMC collected in 2021 and found that homotypic and heterotypic IFNγ responses were significantly boosted in ChAdOx1 recipients but not controls. Finally, we show that in PBMC derived from blood donors, IFNγ responses are made to both conserved and variable regions of the hexon protein. Future vaccination campaigns using adenoviral vectored vaccines will need to account for the pre-existing exposure of recipients to both circulating HAdVs and vaccines such as ChAdOx1, which convey polyfunctional antiviral T cell responses to even low seroprevalence HAdV types.

Indexed as

Adenoviridae InfectionsAdenoviruses, HumanAdenovirus Infections, HumanT-LymphocytesAdultAnimalsChAdOx1 nCoV-19COVID-19COVID-19 VaccinesCross ReactionsFemaleGenetic VectorsHumansImmunity, CellularInterferon-gammaInterleukin-2ChAdOx1 nCoV-19COVID-19 VaccinesInterferon-gammaInterleukin-2cellular immunityDNA virusvaccinationviral vectors

Identifiers

PMID39921609
PMCPMC11806872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.